Key facts
- China aims to rank at the global forefront of drug innovation.
- The country targets having 25% of the world's first-in-class drugs by 2030.
- This goal is driven by government policies and increased R&D investment.
- Focus areas include oncology and rare diseases.
- The strategy involves fostering domestic innovation and attracting international talent.
China is setting an ambitious target to become a global leader in biopharmaceutical innovation, aiming to account for 25% of the world's first-in-class drugs by 2030. This strategic push is underpinned by supportive government policies and a significant increase in investment dedicated to research and development within the pharmaceutical sector.
The nation's focus is particularly directed towards therapeutic areas such as oncology and the treatment of rare diseases. The strategy encompasses fostering homegrown innovation while simultaneously working to attract international scientific talent to bolster the capabilities of its pharmaceutical industry. This initiative signals a shift towards higher-value drug development and away from generic manufacturing, positioning China as a key player in cutting-edge medical advancements.